The results of various studies have suggested that the expressions of stem cell markers, such as NANOG, SOX2, forkhead-box protein M1 (FOXM1), and OCT4, in ovarian cancer mirror their tumorigenic potential, as well as resistance to paclitaxel, cisplatin, methotrexate, and adriamycin cells [211,212]. This evidence concerns the gene SOX2 and ovarian carcinoma.